LabCorp to Announce Second Quarter Financial Results on July 28, 2020
July 06 2020 - 4:25PM
Business Wire
LabCorp (NYSE: LH) will release its
second quarter of 2020 financial results before the market opens on
Tuesday, July 28, 2020, and then will host a conference call and
webcast beginning at 9:00 a.m. EDT to discuss the results. The
earnings release and accompanying financial information will be
posted on the LabCorp Investor Relations website.
Interested parties can access the
conference call by dialing 1-877-898-8036 within the U.S. and
Canada, or 1-720-634-2811 internationally, using the passcode
2597361. In addition, a real-time webcast of the conference call
will be available on the LabCorp Investor Relations website.
An audio replay of the conference call will be available from
1:00 p.m. EDT on July 28, 2020, until 11:30 a.m. EDT on August 11,
2020, by dialing 1-855-859-2056 within the U.S. and Canada, or
1-404-537-3406 internationally, using the passcode 2597361. The
webcast of the conference call will be archived and accessible
through July 14, 2021, on the LabCorp Investor Relations
website.
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global
life sciences company that is deeply integrated in guiding patient
care, providing comprehensive clinical laboratory and end-to-end
drug development services. With a mission to improve health and
improve lives, LabCorp delivers world-class diagnostics solutions,
brings innovative medicines to patients faster, and uses technology
to improve the delivery of care. LabCorp reported revenue of more
than $11.5 billion in 2019. To learn more about LabCorp, visit
www.LabCorp.com, and to learn more about Covance Drug Development,
visit www.Covance.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements,
including but not limited to statements with respect to the impact
of various factors on operating and financial results and the
opportunities for future growth. Each of the forward-looking
statements is subject to change based on various important factors,
many of which are beyond the Company’s control, including without
limitation, the impact of the COVID-19 pandemic on our business and
financial condition as well as on general economic, business, and
market conditions, competitive actions and other unforeseen changes
and general uncertainties in the marketplace, changes in government
regulations, including healthcare reform, customer purchasing
decisions, including changes in payer regulations or policies,
other adverse actions of governmental and third-party payers, the
Company’s satisfaction of regulatory and other requirements,
patient safety issues, changes in testing guidelines or
recommendations, federal, state, and local governmental responses
to the COVID-19 pandemic, adverse results in material litigation
matters, failure to maintain or develop customer relationships, our
ability to develop or acquire new products and adapt to
technological changes, failure in information technology, systems
or data security, changes in business conditions and the economy in
general, adverse weather conditions, the number of revenue days in
a financial period, employee relations, personnel costs, and effect
of exchange rate fluctuations. These factors, in some cases, have
affected and in the future (together with other factors) could
affect the Company’s ability to implement the Company’s business
strategy and actual results could differ materially from those
suggested by these forward-looking statements. As a result, readers
are cautioned not to place undue reliance on any of our
forward-looking statements. The Company has no obligation to
provide any updates to these forward-looking statements even if its
expectations change. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement. Further
information on potential factors, risks and uncertainties that
could affect operating and financial results is included in the
Company’s most recent Annual Report on Form 10-K and subsequent
Forms 10-Q, including in each case under the heading RISK FACTORS,
and in the Company’s other filings with the SEC.
# # #
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200706005561/en/
LabCorp Contacts: Investors: Clarissa Willett —
336-436-5076 Investor@LabCorp.com
Media: Pattie Kushner — 336-436-8263 Media@LabCorp.com
Labcorp (NYSE:LH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Labcorp (NYSE:LH)
Historical Stock Chart
From Sep 2023 to Sep 2024